New Kid Tmunity Banks $100M From Gilead and Facebook Billionaire Sean Parker
The funds raised will partly go towards funding two clinical trials that have already opened. Source: BioSpace
Bay Area's GigaGen Moves to New Space to Accommodate Growth
GigaGen completed relocation to One Tower Place in late December 2017. Source: BioSpace
3 Biotechs That Have Doubled Investors' Money in Less Than a Year
Having a stock double in value is a good thing. Source: BioSpace
Gilead's Kite Pays $135M for Ex-Agensys R&D Building
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County. Source: BioSpace
Amgen Jumps as Migraine Drug Wows in Late-Stage Study
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. Source: BioSpace
Deal Spree Continues as Celgene Nabs Juno in $9B Deal
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace
Hepatares Co-Founder to Helm Merck's New R&D Center in the UK
Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015. Source: BioSpace
Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ
The deal has Sanofi paying $105 per share in cash. Source: BioSpace
Bay Area's Eureka Therapeutics Banks $60M
Acorn Pacific Ventures led the round, with participation from GP Capital and all existing major investors. Source: BioSpace
What You Need to Know About Indalo Therapeutics
Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. Source: BioSpace
- Go to the previous page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- …
- 288
- Go to the next page